Afuco™ Anti-DLL4 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-204) (CAT#: AFC-TAB-204)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to DLL4. It is a humanized monoclonal antibody designed for the treatment of cancer.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Formats:
  • Isotype Switching:
  • Fc Engineering:
  • Modalities:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Normal Tissue
RNA Expression

Specifications

  • Immunogen
  • Partial recombinant DLL4 ragment.
  • Host Species
  • Human
  • Derivation
  • Humanized (from mouse)
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Applications
  • ELISA, FC, IP, FuncS, IF, Neut
  • Conjugate
  • Unconjugated
  • Generic Name
  • Demcizumab
  • Related Disease
  • Cancers

Product Property

  • Purity
  • >95% by SDS-PAGE
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • DLL4; delta-like 4 (Drosophila); delta like 4 homolog (Drosophila); delta-like protein 4; delta4; delta 4; delta ligand 4; notch ligand DLL4; delta-like 4 homolog; delta-like 4 protein; notch ligand delta-2;

Related Resources

  • Biosimilar Overview
Please refer to Demcizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Demcizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Demcizumab"

DrugMonitor™ Anti-Demcizumab Antibody (VS-1224-YC348)
Demcizumab is in clinical investigation for treating nonsquamous non-small cell lung cancer. The DrugMonitor™ Anti-Demcizumab Antibody (VS-1224-YC348) is an anti-drug antibody (ADA) against Demcizumab. This drug-based antibody is raised in mice immunized with the Demcizumab. The anti-Demcizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Demcizumab in samples.

See other products for "DLL4"

Select a product category from the dropdown menu below to view related products.
Please select product type
Humanized Antibody Products Rat Antibody Products Chimeric Antibody Products Mouse Antibody Products Human Antibody Products Blocking Antibody Products Rabbit Monoclonal Antibody Products IgG Antibody Products ScFv Antibody Products Fab Antibody Products Single Domain Antibody Products Antibody Magnetic Beads
CAT Product Name Application Type
TAB-204 Anti-Human DLL4 Recombinant Antibody (TAB-204) ELISA, FC, IP, FuncS, IF, Neut, WB IgG2 - kappa

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for AFC-TAB-204. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare